- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharma
Alkermes PLC+ Add to Watchlist
ALKS:US71.3600 USD 1.5500 2.22%
As of 16:30:00 ET on 01/26/2015.
Company Profile for Alkermes PLC (ALKS)
Alkermes PLC researches pharmaceuticals. The Company develops treatments for central nervous system disorders such as addiction, schizophrenia and depression, and diabetes.
Key Executives for Alkermes PLC (ALKS)
|Richard F PopsChairman/CEO||Shane M CookePresident|
|James M Frates "Jim"Senior VP/CFO/Treasurer||Gordon G PughSenior VP/COO/Chief Risk Ofcr|
|Mark StejbachSenior VP/Chief Commercial Ofcr||Kathryn L BibersteinSenior VP/Secy/General Counsel|
|Michael J Landine "Mike"Senior VP:Corporate Development||Elliot W EhrichSenior VP:R&D/Chief Medical Officer|
|Rebecca J PetersonSenior VP:Corporate Communication|